Glympse Bio raises more than $46M in Series B round for biosensor technology
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.
Alphabet CFO Ruth Porat and Silver Lake Managing Director Egon Durban will be nominated to join Verily's operating board.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The oversubscribed round comes just four months after acquisition of GSK's gene therapy portfolio.
The funding comes as competition for the Medicare population by startup and growth-stage companies intensifies, not only from other technology-led healthcare organizations like Iora but also from the likes of CVS Health and more established companies like CareMore.
The investment could pave the way for the kind of joint ventures and collaborations that Verily has embarked on with the likes of Sanofi, GSK, and others.